Wednesday, March 11, 2020
corona virus
gd morning, welcome back to war, wednesday, 09.15 am
"The regulator had previously set a Feb. 4, 2020, target date for a decision on the Alnylam drug."
"The first RNAi drug, Alnylam Pharmaceuticals’ Onpattro (patisiran), was FDA-approved last August and it is showing long-term efficacy and sustained treatment for the rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). In addition to its fully stocked pipeline, Alnylam now has its eyes set on the next possible FDA approval, with the FDA granting priority review to their investigational RNAi drug for the rare disease acute hepatic porphyria, givosiran"
"The regulator had previously set a Feb. 4, 2020, target date for a decision on the Alnylam drug."
"The first RNAi drug, Alnylam Pharmaceuticals’ Onpattro (patisiran), was FDA-approved last August and it is showing long-term efficacy and sustained treatment for the rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). In addition to its fully stocked pipeline, Alnylam now has its eyes set on the next possible FDA approval, with the FDA granting priority review to their investigational RNAi drug for the rare disease acute hepatic porphyria, givosiran"
XCONOMY.COM
An Alnylam Pharmaceuticals drug developed to treat a rare, inherited metabolic disorder won FDA approval on Wednesday, the second regulatory…
An Alnylam Pharmaceuticals drug developed to treat a rare, inherited metabolic disorder won FDA approval on Wednesday, the second regulatory nod the
Tuesday, March 10, 2020
corona virus
Sonovia’s ultrasonic fabric-finishing technology, invented by two Bar-Ilan University chemistry professors, mechanically infuses antiviral, antimicrobial zinc and copper oxide nanoparticles into textiles for facemasks and other protective products.
Sonovia recently received a European Commission Horizon 2020 grant and the technology has won several prizes in China.
corona virus medication cure
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available. We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations. Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.
Chloroquine Tablets
FROM £5.99
Medication features
- Used for malaria prevention
- Once a week dosage
- Continue for 4 weeks after leaving the zone
Monday, March 9, 2020
"An Israeli air force F-16 has shot down an unmanned air vehicle launched from Lebanon by Hezbollah militants. The threat was detected over the Mediterranean Sea on 25 April 2013 and was destroyed shortly after by an air-to-air missile. The encounter occurred at 13:30 local time, and an air force helicopter transporting Israeli Prime Minister Benjamin Netanyahu for an official visit to the north of the country landed as fighters scrambled. Israel's latest interception of a UAV is the fifth such action to have been performed by its air force in the past decade." (Israel folder)
welcome back to war, another week, monday, 09.44 am
"A toxin agent is most effective when prepared as a freeze-dried powder and encapsulated. Such encapsulation, however, is not necessary for weaponization. Infectious biological agents are generally stabilized and then spray dried.13
Under appropriate meteorological conditions and with an aerosol generator delivering 1-5 micron particle-size droplets, a single aircraft can disperse 100 kg of anthrax over a 300 km 2 area and theoretically cause 3 million deaths in a population density of 10,000 people per km2. The mean lethal inhalator dosage is 10 nanograms."
Subscribe to:
Posts (Atom)